Latest news with #CTT
Associated Press
10-03-2025
- Business
- Associated Press
CTT Pharma Uplists to the OTCQB Today
TAMPA, FL / ACCESS Newswire / March 9, 2025 / CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has entered the OTCQB Market today under the ticker symbol 'CTTH'. CTT Pharma's CEO will issue a news release to shareholders this Wednesday March 12, 2025. About CTT Pharmaceuticals Holdings, Inc. CTT has patented technology in the United States, Europe, Canada and many additional countries to allow many actives on a dissolvable strip that include but are not limited to Nicotine, Vitamins, and Pharmaceuticals. CTT believes that there is a need for our technology in many industries, which includes a smoke-free nicotine strip that can be used as a smoking cessation product and delivering drugs that can help with pain management and anxiety. CTT Pharma incorporates micelle technology into its drug delivery. These strips dissolve quickly, deliver low dose options and offer better bioavailability.
Associated Press
05-03-2025
- Business
- Associated Press
CTT Pharmaceuticals Holdings, Inc. Announces Uplisting to OTCQB Market Trading
TAMPA, FL / ACCESS Newswire / March 5, 2025 / CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) is pleased to announce the OTC Markets Group has approved the trading of its common shares on the OTCQB Market. The company's common shares will trade on the OTCQB under the symbol 'CTTH' as of the opening of the market on March 10, 2025. Uplisting to the OTCQB should provide CTT with greater liquidity and a more seamless trading experience for U.S. shareholders. The OTCQB is a premier marketplace for Pharmaceutical companies in early stage that are moving towards development of new technology. Companies listed on the OTCQB are current in their reporting and undergo yearly PCAOB Audits. CTT will make a formal announcement on March 10, 2025 announcing the uplisting to the OTCQB investor community. The CEO of CTT Pharma will issue a news release to shareholders on March 12, 2025. CTT Pharma - 813-606-0060 SOURCE: CTT Pharmaceutical Holdings, Inc.
Yahoo
17-02-2025
- Business
- Yahoo
CTT Confirms Anti-Condensation Retrofit Order for 146 Airbus A321neo Aircraft from Jet2.com
NYKÖPING, SWEDEN / / February 17, 2025 / CTT Systems AB (STO:CTT) CTT SYSTEMS AB ("CTT"), the market leader of aircraft humidity control systems, confirms that leading leisure airline is the undisclosed customer that in January 2025 ordered 146 Anti-Condensation systems to be retrofitted in 146 Airbus A321neos, with optional purchase rights for additional nine systems. Deliveries of the first 30 systems will commence in Q3 2025 and are scheduled to be completed in 2028. Delivery dates for the remaining order of 125 systems are not yet specified, but all deliveries shall be completed no later than 2035. The Anti-Condensation systems will be installed at the first C-check for every aircraft. has 13 A321neo aircraft in-service from a firm order of 146 aircraft. has been a CTT customer since 2007 and since then has fitted over 100 of its Boeing and Airbus aircraft with the Anti-Condensation system to moisture protect aircraft and reduce fuel consumption. "We are pleased to receive another order from ," says Peter Landquist, Vice President Senior Advisor Sales." is a valued customer and leading operator in the UK with its policy to moisture-protect aircraft, which prevents unwanted excess weight and achieves numerous operational benefits." The CTT Anti-Fuselage-Condensation system removes trapped water in blankets, keeps the crown area dry and prevents unwanted excess weight from water accumulation. Airlines hereby operate with lower energy needs and less pollutant emissions. A 200 - 300 kg weight reduction on Airbus A321neo aircraft generates the following advantages:· Reducing fuel burn with estimated 0.4 - 0.6% and· Cutting CO2 emissions with approx. 65 - 95 tons per aircraft per year with fuel savings of approx. 25,000 - 38,000 liters per year,· Higher operational reliability from significantly lowered moisture-related faults in electrical equipment (reduced Out-Of-Service time and repair costs)· Lower rate of insulation blanket replacement. For additional information: Peter Landquist, VP Senior Advisor Sales, CTT Systems +46 155-20 59 02 alt. Mobile +46 70-665 24 45 or email: Häggfeldt, CCO, CTT Systems +46 155-20 59 30 alt. Mobile +46 70-279 77 33 or email: About CTT Systems CTT is the leading supplier of active humidity control systems in aircraft. We solve the aircraft humidity paradox - with far too dry cabin air - and too much moisture in the fuselage - causing dehydration for people onboard and excess weight in the aircraft inducing larger environmental footprint. CTT offers humidifiers and dehumidifiers available for retrofit and line-fit on commercial aircraft as well as private jets. For more information about CTT and how active humidity control products make air traveling a little more sustainable and far more pleasurable, please visit: Attachments CTT confirms Anti-Condensation retrofit order for 146 Airbus A321neo aircraft from SOURCE: CTT Systems AB View the original press release on ACCESS Newswire Sign in to access your portfolio
Associated Press
12-02-2025
- Business
- Associated Press
CTT Pharma Gives Update On NSF Grant
TAMPA, FL / ACCESS Newswire / February 12, 2025 / CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) submitted a full proposal to the National Science Foundation(NSF) for our patented fast dissolving nicotine strips. The NSF grant program is highly competitive as it receives over 12,000 applicants annually from companies that have innovations that could help society. CTT successfully made it past the first round process and is among a few thousand remaining applicants. These remaining applicants have several deadlines over the course of the year to file a full proposal into the grant program. CTT is anticipating an answer in this program in late April. Acceptance into this program would give government backing to CTT Pharma and would allow for extensive research and testing to help lead to development of our technology. The World Health Organization states, 'The tobacco epidemic is one of the biggest public health threats the world has ever faced, killing over 8 million people a year around the world. More than 7 million of those deaths are results of direct tobacco use while 1.3 million are the result of non-smokers being exposed to second-hand smoke.' Furthermore, the CDC says, 'Cigarette smoking is the leading cause of preventable death in the United States. Cigarette smoking causes more than 480,000 deaths each year in the United States. This is nearly 1 in 5 deaths. The CEO of CTT Pharma, Ryan Khouri stated, 'To make it past the first round of applicants is a huge accomplishment by itself and shows that the NSF sees potential value for our technology within the tobacco industry. Currently there are no fast dissolving, low dose nicotine strips on the market, as most oral products stay in the mouth for an excessive amount of time. CTT also brought someone onto our team to help with this NSF Grant as they have a tremendous amount of experience with the NSF.' CTT Pharma - 813-606-0060 SOURCE: CTT Pharmaceutical Holdings, Inc.
Associated Press
05-02-2025
- Business
- Associated Press
CTT Pharma Adds Independent Director With NIH/NSF Experience
TAMPA, FL / ACCESS Newswire / February 5, 2025 / CTT Pharmaceuticals Holdings, Inc. (OTC PINK:CTTH) is pleased to announce adding Dr. Katherine Cole as an Independent Director for CTT. Dr. Cole. a Ph.D. in Pathology from the University of Maryland School of Medicine. Following her Ph.D. she spent 3 years at the National Cancer Institute(NCI) at the National Institutes of Health(NIH) where she spent her time focused on anti-cancer mechanisms of novel chemotherapeutic compounds. From there Dr. Cole worked at four different universities as a Biomedical scientist, professor, and eventually as a vice Provost and Dean. She has published twenty-two peer reviewed papers and has been granted two patents related to a human liver cell line. Dr. Cole has been awarded many notable grants including grants from the National Science Foundation(NSF) and the Howard Hughes Medical Institute. Dr. Cole's professional development as a scientist, an educator and a university-level administrator has provided her with a distinct scientific perspective and an ability to critically analyze meaningful data and research design. Her Ph.D. in Pathology from the University of Maryland School of Medicine and postdoctoral experience at the NIH/NCI in cancer research have positioned her well to not only understand the science behind this technology, but the impact from a human pathological perspective. CTT is honored to have Dr. Cole on our team and looks forward to her contributions. About CTT Pharmaceuticals Holdings, Inc. CTT has patented technology in The United States, Europe, Canada and many additional countries to allow many actives on a dissolvable strip that include but are not limited to Nicotine, Vitamins, and Pharmaceuticals. CTT believes that there is a need for our technology in many industries, which includes a smoke-free nicotine strip that can be used as a smoking cessation product and deliver drugs that can help with pain management and anxiety. CTT Pharma incorporates micelle technology into its drug delivery. These strips would dissolve quickly, deliver low dose options and offer better bioavailability.
